Monday, January 29, 2024
BIOTRONIK proudly announces a significant achievement: over 100,000 single lead implantable cardioverter-defibrillators (ICDs) equipped with DX Technology have been successfully implanted. This milestone highlights BIOTRONIK's leadership and dedication to advancing cardiac rhythm management. DX Technology is distinguished by its capability to directly sense atrial activity, enabling the detection and monitoring of atrial fibrillation (AF). AF often goes undetected in patients with ICDs, with approximately 21 percent of cases being missed annually.
Traditional single-chamber ICDs lack the ability to sense atrial activity, making AF detection challenging. DX Technology, integrated into single-lead ICD systems with a floating atrial dipole, provides reliable detection and monitoring of atrial arrhythmias, including AF. This early detection facilitates timely intervention and allows clinicians to adjust treatment plans as needed.
When coupled with BIOTRONIK Home Monitoring®, this integrated solution offers a comprehensive approach to patient management, enabling informed decision-making and proactive AF management. The recent findings from the MATRIX study further support the effectiveness of DX Technology in real-world settings, particularly in facilitating remote monitoring of subclinical AF in accordance with guidelines.
Source: prnewswire.com
